Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 35048357.
- Also identified by DOI 10.1111/bjd.21022.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Enfortumab vedotin (EV), a novel antibody-drug conjugate approved for metastatic urothelial carcinoma, causes a variety of cutaneous adverse reactions. We present two cases of bullous eruptions following treatment with EV, both demonstrating IgG deposition on direct immunofluorescence (DIF) correlating to the location of nectin-4 in the epidermis. This suggests that the IgG component of EV binding to nectin-4 in keratinocytes is likely a primary contributor to the high rates of cutaneous toxicity.
Medical subject headings
- Antibodies, Monoclonal
- Carcinoma, Transitional Cell
- Drug Eruptions
- Urinary Bladder Neoplasms